Mylan (MYL) Receives FDA Approval for Carvedilol Tablets
More News related to GSK
- Susquehanna Initiates Coverage on Theravance (THRX) with a Positive
- GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
- Valeant Pharmaceuticals (VRX) and GlaxoSmithKline Enter Collaboration for Retigabine
- GlaxoSmithKline To Post Quarterly US Grants Report
- New Study Suggests Increasing Prescription Co-payments for Chronic Diseases May Worsen Health Disparities, Adversely Affect Health
More News related to MYL
- Mylan (MYL) Subsidiary Announces Favorable Court Ruling Against Barr Labs (BRL)
- Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
- Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne(R) Tablets
- Loeb's Third Point Buys Into Starwood (HOT) and Tibco (TIBX), Dumps Yahoo! (YHOO)
- Mylan Named Manufacturer of the Year by AmerisourceBergen Corporation
Mylan Laboratories Inc. (NYSE: MYL) received final approval from the FDA for its Abbreviated New Drug Application for Carvedilol Tablets, 3.125 mg, 6.25 mg, 12.5 mg and 25 mg.
Carvedilol Tablets are the generic version of GlaxoSmithKline's Coreg Tablets.
Related Categories
Corporate NewsStocks Mentioned
+0.14
-0.34Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
